Team studying rare disorder discovers novel way to target melanoma

By Jan Jarvis

Wang 2

While studying a rare genetic disorder called NGLY1 deficiency, UNT Health Science Center researchers discovered a new targeted treatment for combating melanoma, a skin cancer that kills about 9,000 people in the United States each year.

Their research was recently published in the British Journal of Cancer.

The discovery came when UNT System College of Pharmacy scientists were studying a missing protein that plays a role in NGLY1 deficiency, a disorder so rare that only about 60 patients worldwide have been diagnosed since it was identified in 2012. While trying to understand this newly identified genetic disorder, the team discovered that melanoma cells are surprisingly vulnerable to the loss of NGLY1 activity, said Yu-Chieh Wang, PhD, senior author and Assistant Professor of Pharmaceutical Sciences.

“People born with NGLY1 deficiency are alive while presenting developmental delays,” Dr. Wang said. “But when we studied the developmental variations caused by NGLY1, we found that the NGLY1 protein could be a very attractive cancer target.”

The team began exploring how the protein acts in the body and discovered that when NGLY1 was inhibited, normal cells survived — but melanoma cells did not.

“When melanoma cells lose NGLY1, they in fact die very quickly,” Dr. Wang said.

The study suggests that it is possible to eliminate melanoma cells without harming healthy cells by targeting NGLY1. The research could apply to other cancers as well. The next step is to understand why normal cells and some individuals survive even when the protein is missing, while cancer cells cannot survive without it.

Once a potential target has been identified, it could take more than 15 years before a drug that acts on the target to treat melanoma or other cancers reaches the marketplace.

“A promising discovery like ours could one day provide another way to overcome the cancer burden in humans,” Dr. Wang said. “We will continuously work toward that goal based on our research findings.”

The discovery of a new anticancer target has been exciting, said Victor Lin, a graduate student in the Wang Lab and a lead author of the research article.

“We are proud of this work – and expect to ultimately demonstrate that targeting NGLY1 is a viable anticancer approach for patients in the future,” he said.

Additional UNTHSC authors include research specialist Ashwini Zolekar, student pharmacist Rohit Sampat, postdoctoral fellows Nigam Mishra and Hamed Hayatshahi, Assistant Professor of Pharmaceutical Sciences Jin Liu and Professor of Pharmaceutical Sciences Kyle Emmitte. Other contributing authors were from Purdue University, University of California-San Diego, University of Adelaide and University of Southern Australia.

The research is supported by funds from the National Institutes of Health, Cancer Prevention and Research Institute of Texas and American Medical Association Foundation. The article is entitled “Stress and interferon signaling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1.”

Recent News

Dr. John Licciardone
  • Research
|Jun 12, 2025

Long-term study shows better chronic pain outcomes in patients treated by osteopathic physicians

The first long-term study involving three years of follow-up of osteopathic medical care for chronic pain has been published in the Journal of Osteopathic Medicine. The research team was led by Dr. John Licciardone, executive director of the Osteopathic Research Center and regents professor at T...
Dsc01266
  • Community
|Jun 12, 2025

Legacy Writers: TCOM students bring life stories to the final chapter

When Azelia Lau arrived at the Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth, she brought more than a passion for psychiatry. She also carried a long-held idea inspired by an undergraduate program she never got to join. Now a third-...
Lillee Smith Gelinas 666 X 750
  • Research
|Jun 5, 2025

TCOM course linked to higher patient safety awareness knowledge and residency readiness

The Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth is the first medical school in the country to require a patient safety course that prepares students for the Certified Professional in Patient Safety credential — and a new study publishe...
Web Banners
  • Community
|May 30, 2025

TCOM retired faculty member Dr. Frank Papa named emeritus professor by UNT Board of Regents

With more than 40 years of experience, expertise and dedication to the Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth, the UNT System Board of Regents has awarded Frank Papa, DO, Ph.D., with the designation of emeritus professor. Dr. Pa...